- Home
- TGI vs NVCR Comparison
TGI vs NVCR Comparison
Compare TGI & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGI
- NVCR
- Stock Information
- Founded
- TGI 1993
- NVCR 2000
- Country
- TGI United States
- NVCR Switzerland
- Employees
- TGI N/A
- NVCR N/A
- Industry
- TGI Aerospace
- NVCR Medical/Dental Instruments
- Sector
- TGI Industrials
- NVCR Health Care
- Exchange
- TGI Nasdaq
- NVCR Nasdaq
- Market Cap
- TGI 2.0B
- NVCR 1.9B
- IPO Year
- TGI 1996
- NVCR 2015
- Fundamental
- Price
- TGI $25.89
- NVCR $18.15
- Analyst Decision
- TGI Hold
- NVCR Buy
- Analyst Count
- TGI 8
- NVCR 7
- Target Price
- TGI $20.63
- NVCR $32.43
- AVG Volume (30 Days)
- TGI 2.0M
- NVCR 1.5M
- Earning Date
- TGI 08-06-2025
- NVCR 07-24-2025
- Dividend Yield
- TGI N/A
- NVCR N/A
- EPS Growth
- TGI N/A
- NVCR N/A
- EPS
- TGI 0.52
- NVCR N/A
- Revenue
- TGI $1,261,962,000.00
- NVCR $621,711,000.00
- Revenue This Year
- TGI $9.20
- NVCR $5.56
- Revenue Next Year
- TGI $6.89
- NVCR $9.19
- P/E Ratio
- TGI $49.33
- NVCR N/A
- Revenue Growth
- TGI 5.87
- NVCR 18.27
- 52 Week Low
- TGI $11.01
- NVCR $14.17
- 52 Week High
- TGI $25.96
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- TGI 61.85
- NVCR 52.02
- Support Level
- TGI $25.70
- NVCR $16.81
- Resistance Level
- TGI $25.91
- NVCR $18.70
- Average True Range (ATR)
- TGI 0.10
- NVCR 0.73
- MACD
- TGI 0.00
- NVCR 0.04
- Stochastic Oscillator
- TGI 92.61
- NVCR 62.75
About TGI Triumph Group Inc.
Triumph Group Inc designs and manufactures a broad portfolio of aerostructures, aircraft components, and systems for the aviation industry. It serves a customer base of players in the commercial, business, and military markets. The company operates under two operating segments: Systems and Support, which derives key revenue and designs, develops, and supports proprietary components; and Interiors, which supplies commercial and regional manufacturers with aircraft interior systems.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.